View Older Stories View More Recent Stories

Feb 22, 2017 06:00PM Bristol-Myers Squibb Prices $1.5 Billion of Senior Notes
Feb 21, 2017 07:01AM Bristol-Myers Squibb (BMY) Announces $2B Accelerated Share Repurchase and Names Three New Independent Directors in Agreement with JANA
Feb 21, 2017 06:59AM Bristol-Myers Squibb Appoints Three New Independent Directors
Feb 14, 2017 03:41PM JANA Partners Enters Aetna (AET), Bristol-Myers Squibb (BMY), Lamb Weston (LW), Salesforce (CRM) (more...) - 13F
Feb 8, 2017 10:54AM Bristol-Myers Squibb to Take Part in Leerink 6th Annual Global Health Care Conference
Feb 2, 2017 04:41PM Bristol-Myers Squibb (BMY) Confirms FDA Approval for Opdivo in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
Feb 2, 2017 04:15PM Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma, a Type of Bladder Cancer
Feb 2, 2017 09:21AM Cancer Survivors Need More Efficient Integrated Long-Term Care and Stronger Policies Across Healthcare, Advocacy and the Workplace, New Research Concludes
Feb 1, 2017 12:22PM Bristol-Myers Squibb (BMY) Says EPO Upheld Decision That Found '038 Patent Invalid
Feb 1, 2017 12:19PM Bristol-Myers Squibb Announces European Patent Office Decision on Sprycel
Jan 26, 2017 06:59AM Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2016 Financial Results
Jan 20, 2017 04:02PM Bristol-Myers Squibb (BMY), Ono Enter Settlement and License Agreement with Merck (MRK) to Resolve PD-1 Antibody Patent Litigation
Jan 20, 2017 04:01PM Bristol-Myers Squibb and Ono Pharmaceutical Company Enter Settlement and License Agreement with Merck to Resolve PD-1 Antibody Patent Litigation
Jan 20, 2017 07:24AM Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
Jan 19, 2017 06:30PM Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer
Jan 19, 2017 09:00AM Opdivo (nivolumab) Demonstrated Efficacy and Improved Survival in Patients with Previously Treated Advanced Gastric Cancer in a Randomized Phase 3 Study
Jan 6, 2017 07:05AM Bristol-Myers Squibb (BMY) Announces Biomarker Research Collaboration with GeneCentric Diagnostics
Jan 6, 2017 06:59AM Bristol-Myers Squibb and GeneCentric Diagnostics Announce Exploratory Biomarker Research Collaboration
Jan 5, 2017 07:05AM Bristol-Myers Squibb (BMY) Enters Collaboration with JNJ's (JNJ) Janssen for Opdivo/Darzalex Combo
Jan 5, 2017 06:59AM Bristol-Myers Squibb Announces Immunotherapy Clinical Collaboration with Janssen to Evaluate Opdivo (nivolumab) in Combination with Darzalex (daratumumab)
Jan 3, 2017 09:18AM Bristol-Myers Squibb to Present at J.P. Morgan Healthcare Conference
Dec 29, 2016 09:00AM Bristol-Myers Squibb to Take Part at the Goldman Sachs Healthcare CEOs Unscripted: A View from the Top
Dec 21, 2016 08:30AM Giovanni Caforio Named Chairman of Bristol-Myers Squibb’s Board of Directors
Dec 21, 2016 07:01AM Bristol-Myers Squibb (BMY) and Calithera Biosciences (CALA) Enter Pact to Evaluate Opdivo in Combination with CB-839 in ccRCC
Dec 21, 2016 06:59AM Bristol-Myers Squibb and Calithera Biosciences Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with CB-839 in Clear Cell Renal Cell Carcinoma
Dec 21, 2016 06:59AM Bristol-Myers Squibb and Calithera Biosciences Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with CB-839 in Clear Cell Renal Cell Carcinoma
Dec 20, 2016 07:00AM Bristol-Myers Squibb (BMY) Licenses 'Armed' Oncolytic Virus NG-348 from PsiOxus Therapeutics
Dec 20, 2016 06:59AM Bristol-Myers Squibb Signs Exclusive Worldwide License Agreement with PsiOxus Therapeutics for NG-348, an “Armed” Oncolytic Virus to Address Solid Tumors
Dec 19, 2016 08:04AM Portola Pharma (PTLA) Enters $50M Loan Agreement with Bristol-Myers Squibb (BMY) and Pfizer (PFE) to Continue AndexXa Development
Dec 19, 2016 08:00AM Portola Pharmaceuticals Enters into $50 Million Loan Agreement with Bristol-Myers Squibb and Pfizer for Continued Development of AndexXa™ (andexanet alfa)
Dec 13, 2016 09:30AM Bristol-Myers Squibb Strengthens Capabilities with Evolution of its U.S. Geographic Footprint
Dec 9, 2016 04:00PM Bristol-Myers Squibb to Announce Results for Fourth Quarter 2016 on January 26, 2017
Dec 8, 2016 04:15PM Bristol-Myers Squibb Announces Dividend Increase
Dec 6, 2016 08:48AM Bristol-Myers Squibb (BMY) Opdivo Showed Encouraging Response and Survival Rates in SCLC Alone or Combined With Yervoy
Dec 6, 2016 08:45AM Opdivo (nivolumab) Alone or Combined With Yervoy (ipilimumab) Shows Encouraging Response and Survival Rates in Recurrent Small Cell Lung Cancer, From Phase 1/2 Study CheckMate -032
Dec 6, 2016 06:18AM Seattle Genetics (SGEN), Bristol-Myers (BMY) Present First Data from ADCETRIS + Opdivo Phase 1/2 in r/r HL
Dec 5, 2016 07:30PM Seattle Genetics and Bristol-Myers Squibb Highlight First Data from Phase 1/2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) in Combination with Opdivo (nivolumab) in Relapsed or Refractory Hodgkin
Dec 5, 2016 06:07AM Bristol-Myers Squibb (BMY) Announces Positive Updated Opdivo Combo Phase 1b Data in NDCLC
Dec 5, 2016 05:00AM Encouraging Survival Observed With Opdivo (nivolumab) Plus Yervoy (ipilimumab) With Longer Follow-up in First-line Advanced Non-small Cell Lung Cancer, in Updated Phase 1b CheckMate -012 Study
Nov 30, 2016 09:54AM Bristol-Myers Squibb to Take Part at the Citi 2016 Global Healthcare Conference
Nov 22, 2016 03:02PM Bristol-Myers Squibb (BMY) Announces EC Approval for Opdivo to Treat Relapsed or Refractory Classical Hodgkin Lymphoma
Nov 22, 2016 03:00PM European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab) for the Treatment of Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplan
Nov 22, 2016 08:04AM QuintilesIMS (Q) Enters anti-Cancer Treatment Collaborations with Leading Pharma Companies (PFE) (BMY)
Nov 16, 2016 05:14PM Bristol-Myers Squibb (BMY) Presents New Opdivo + Yervoy Data at IASLC 17th WCLC
Nov 16, 2016 05:13PM Bristol-Myers Squibb Presents New Data at IASLC 17th World Conference on Lung Cancer Underscoring Progress and Leadership in Broad Lung Development Program
Nov 16, 2016 06:25AM Bristol-Myers Squibb (BMY), Enterome Enter Immuno-Oncology Collaboration for Microbiome-Derived Biomarkers Development
Nov 16, 2016 04:04AM Bristol-Myers Squibb and Enterome SA Announce Immuno-Oncology Collaboration Focused on Microbiome-derived Biomarkers, Drug Targets and Bioactive Molecules
Nov 16, 2016 03:00AM Bristol-Myers Squibb and Enterome Announce Immuno-Oncology Collaboration Focused on Microbiome-Derived Biomarkers, Drug Targets and Bioactive Molecules
Nov 14, 2016 07:10AM Bristol-Myers Squibb (BMY) Announces Additional CheckMate-032 Phase 1/2 Data in Previously Treated mUC Patients
Nov 14, 2016 06:59AM Bristol-Myers Squibb Showcases Rheumatoid Arthritis and Immunoscience Commitment with Depth of Research at 2016 American College of Rheumatology and Association of Rheumatology Health Professionals An
View More Recent Stories View Older Stories